JACOBSON PHARMA (02633) announces its interim performance with a net profit attributable to shareholders of 142 million Hong Kong dollars, representing a year-on-year increase of 1.24%.
Jacobson Pharmaceutical (02633) released its mid-term performance in 2025, with the group achieving a revenue of HKD 7.67 billion during the period.
Jacobson Pharma (02633) announced its mid-year performance for 2025. The group achieved a revenue of HK$767 million, a decrease of 5.36% compared to the same period last year. The net profit attributable to equity holders of the company was HK$142 million, an increase of 1.24% year-on-year. Basic earnings per share were 7.12 HK cents. The mid-year dividend per share was 4.25 HK cents.
Related Articles
Sichuan Joyou Digital Technologies' shareholder Chengdu Gaochuang Investment plans to reduce its shareholding by no more than 1%.
An Hui Shun Yu Water (301519.SZ) plans to establish a subsidiary in Hainan and a subsidiary in Hong Kong.
Fujian Superpipe (300198.SZ) subsidiary Liancheng Shuifa's legal representative Lin Huixia has been restricted from high consumption.
Sichuan Joyou Digital Technologies' shareholder Chengdu Gaochuang Investment plans to reduce its shareholding by no more than 1%.
An Hui Shun Yu Water (301519.SZ) plans to establish a subsidiary in Hainan and a subsidiary in Hong Kong.
Fujian Superpipe (300198.SZ) subsidiary Liancheng Shuifa's legal representative Lin Huixia has been restricted from high consumption.
RECOMMEND
U.S. equities face “key defense lines,” testing bullish conviction; a break would confirm a downtrend into “early next year”
17/11/2025
Year-to-date Hong Kong share buybacks surpass HK$140 billion, with technology and financials leading activity
17/11/2025
Bitcoin’s year-to-date 30% rally “fully erased,” market slips into a bear phase
17/11/2025
